Patents by Inventor E. Scott Priestley

E. Scott Priestley has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • 3,4-disubstituted benzamidines and benzylamines, and analogues thereof, useful as serine protease inhibitors
    Patent number: 7247654
    Abstract: The present invention relates generally to compounds that inhibit serine proteases. In particular it is directed to novel 3,4-disubstituted benzamidines and benzylamines, or a stereoisomer or pharmaceutically acceptable salt form thereof, which are useful as selective inhibitors of serine protease enzymes of the coagulation cascade; for example thrombin, factor Xa, factor XIa, factor IXa, and/or factor VIIa. In particular, it relates to compounds that are factor VIIa inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of using the same.
    Type: Grant
    Filed: June 1, 2004
    Date of Patent: July 24, 2007
    Assignee: Bristol-Myers Squibb Company
    Inventors: E. Scott Priestley, Xiaojun Zhang
  • Lactam inhibitors of Hepatitis C virus NS3 protease
    Patent number: 7122627
    Abstract: The present invention relates to lactams of Formula (I): or stereoisomeric forms, stereoisomeric mixtures, or pharmaceutically acceptable salt forms thereof, which are useful as inhibitors of HCV NS3 protease, and to pharmaceutical compositions and diagnostic kits comprising the same, and methods of using the same for treating viral infection or as an assay standard or reagent.
    Type: Grant
    Filed: December 6, 2001
    Date of Patent: October 17, 2006
    Assignee: Bristol-Myers Squibb Company
    Inventors: E. Scott Priestley, Carl P. Decicco
  • Phenylglycine derivatives useful as serine protease inhibitors
    Patent number: 7122559
    Abstract: Compounds having the formula (I), or a stereoisomer or pharmaceutically-acceptable salt, or hydrate thereof, are useful as factor VIIa inhibitors, wherein X is —NR6S(O)pR16; W is hydrogen or —(CR7R8)q—W1; W1 is hydrogen or a bond with R6; Z is a 5-membered heteroaryl group, a five to six membered heterocyclo or cycloalkyl group, a 9 to 10 membered bicyclic aryl or heteroaryl, or a six membered aryl or heteroaryl, and R1, R2, R3, R6, R7, and R16 are as defined in the specification.
    Type: Grant
    Filed: February 10, 2004
    Date of Patent: October 17, 2006
    Assignee: Bristol-Myers Squibb Company
    Inventors: Peter W. Glunz, Gregory S. Bisacchi, George C. Morton, Alexandra A. Holubec, E. Scott Priestley, Xiaojun Zhang, Uwe D. Treuner
  • Methods of treating factor VIIa-associated conditions with compounds having an amine nucleus
    Patent number: 7041692
    Abstract: Methods of treating Factor VIIa-associated conditions in a mammal are described, comprising administering to the mammal in need of treatment thereof an effective amount of at least one compound having the formula (I), or a pharmaceutically-acceptable salt, hydrate or prodrug thereof.
    Type: Grant
    Filed: June 17, 2003
    Date of Patent: May 9, 2006
    Assignee: Bristol-Myers Squibb Company
    Inventors: Timothy Herpin, Gregory S. Bisacchi, Zulan Pi, E. Scott Priestley, T. G. Murali Dhar
  • Peptide inhibitors of hepatitis C virus NS3 protease
    Patent number: 6939854
    Abstract: This invention relates to a novel class of peptides having the Formula (I): which are useful as serine protease inhibitors, and more particularly as Hepatitis C virus (HCV) NS3 protease inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of using the same in the treatment of HCV infection.
    Type: Grant
    Filed: January 15, 2004
    Date of Patent: September 6, 2005
    Assignee: Bristol-Myers Squibb Pharma Company
    Inventor: E. Scott Priestley
  • Ureido-substituted aniline compounds useful as serine protease inhibitors
    Patent number: 6846838
    Abstract: Compounds having the formula (I), or pharmaceutically-acceptable salts, hydrates or prodrugs thereof, are effective as inhibitors of Factor VIIa.
    Type: Grant
    Filed: June 17, 2003
    Date of Patent: January 25, 2005
    Assignee: Bristol-Myers Squibb Company
    Inventors: William A. Slusarchyk, Scott A. Bolton, Timothy Herpin, Gregory S. Bisacchi, Zulan Pi, E. Scott Priestley
  • Peptide inhibitors of Hepatitis C virus NS3 protein
    Patent number: 6846806
    Abstract: This invention relates to a novel class of peptides having the Formula (I): which are useful as serine protease inhibitors, and more particularly as Hepatitis C virus(HCV) NS3 protease inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of using the same in the treatment of HCV infection.
    Type: Grant
    Filed: October 23, 2001
    Date of Patent: January 25, 2005
    Assignee: Bristol-Myers Squibb Company
    Inventor: E. Scott Priestley
  • Phenylglycine derivatives useful as serine protease inhibitors
    Publication number: 20040204412
    Abstract: Compounds having the formula (I), 1
    Type: Application
    Filed: February 10, 2004
    Publication date: October 14, 2004
    Inventors: Peter W. Glunz, Gregory S. Bisacchi, George C. Morton, Alexandra A. Holubec, E. Scott Priestley, Xiaojun Zhang, Uwe D. Treuner
  • Peptide inhibitors of hepatitis C virus NS3 protease
    Publication number: 20040147483
    Abstract: This invention relates to a novel class of peptides having the Formula (I): 1
    Type: Application
    Filed: January 15, 2004
    Publication date: July 29, 2004
    Inventor: E. Scott Priestley
  • Methods of treating factor VIIa-associated conditions with compounds having an amine nucleus
    Publication number: 20040029940
    Abstract: Methods of treating Factor VIIa-associated conditions in a mammal are described, comprising administering to the mammal in need of treatment thereof an effective amount of at least one compound having the formula (I), 1
    Type: Application
    Filed: June 17, 2003
    Publication date: February 12, 2004
    Inventors: Timothy Herpin, Gregory S. Bisacchi, Zulan Pi, E. Scott Priestley, T.G. Murali Dhar
  • Ureido-substituted aniline compounds useful as serine protease inhibitors
    Publication number: 20040019085
    Abstract: Compounds having the formula (I), 1
    Type: Application
    Filed: June 17, 2003
    Publication date: January 29, 2004
    Inventors: William A. Slusarchyk, Scott A. Bolton, Timothy Herpin, Gregory S. Bisacchi, Zulan Pi, E. Scott Priestley
  • Novel lactam inhibitors of hepatitis C virus NS3 protease
    Publication number: 20030008828
    Abstract: The present invention relates to lactams of Formula (I): 1
    Type: Application
    Filed: December 6, 2001
    Publication date: January 9, 2003
    Inventors: E. Scott Priestley, Carl P. Decicco
  • Peptide inhibitors of hepatitis C virus NS3 protein
    Publication number: 20020177725
    Abstract: This invention relates to a novel class of peptides having the Formula (I): 1
    Type: Application
    Filed: October 28, 2001
    Publication date: November 28, 2002
    Inventor: E. Scott Priestley
  • Nucleic acid binders having an hydroxyamine motif
    Patent number: 6120997
    Abstract: The invention relates to the combination of hydroxyamines with nucleic acid binding motifs to generate molecules and libraries of molecules targeting specific nucleic acid sequences. In particular, a series of libraries are constructed which contain hydroxyamine functionalities that are attached to various template backbones which display varying degrees of molecular recognition to phosphodiesters and varying degrees of sequence specific recognition to nucleic acids.
    Type: Grant
    Filed: January 13, 1998
    Date of Patent: September 19, 2000
    Assignee: The Scripps Research Institute
    Inventors: Chi-Huey Wong, Martin Hendrix, Phil Alper, E. Scott Priestley